Amarin Corp. PLC (NASDAQ:AMRN) shares were up 7.1% during mid-day trading on Friday . The company traded as high as $2.58 and last traded at $2.56, with a volume of 6,465,620 shares trading hands. The stock had previously closed at $2.39.

Several research analysts recently commented on the company. Jefferies Group reissued a “buy” rating on shares of Amarin Corp. PLC in a research note on Wednesday, June 8th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Amarin Corp. PLC in a research note on Monday, May 9th. Finally, Zacks Investment Research raised Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th.

The company’s 50-day moving average is $2.21 and its 200-day moving average is $1.77. The stock’s market capitalization is $488.77 million.

Amarin Corp. PLC (NASDAQ:AMRN) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.03. The firm earned $25.30 million during the quarter, compared to analyst estimates of $26.77 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. The company’s revenue for the quarter was up 60.4% on a year-over-year basis. On average, analysts predict that Amarin Corp. PLC will post ($0.49) earnings per share for the current year.

A hedge fund recently raised its stake in Amarin Corp. PLC stock. OppenheimerFunds Inc. increased its position in shares of Amarin Corp. PLC (NASDAQ:AMRN) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,323,360 shares of the biopharmaceutical company’s stock after buying an additional 27,090 shares during the period. OppenheimerFunds Inc. owned about 2.90% of Amarin Corp. PLC worth $10,061,000 as of its most recent SEC filing.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.